Details for New Drug Application (NDA): 020918
✉ Email this page to a colleague
NDA 020918 describes GLUCAGEN, which is a drug marketed by Novo Nordisk and is included in one NDA. Additional details are available on the GLUCAGEN profile page.
The generic ingredient in GLUCAGEN is glucagon hydrochloride. There are twelve drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the glucagon hydrochloride profile page.
The generic ingredient in GLUCAGEN is glucagon hydrochloride. There are twelve drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the glucagon hydrochloride profile page.
Summary for 020918
| Tradename: | GLUCAGEN |
| Applicant: | Novo Nordisk |
| Ingredient: | glucagon hydrochloride |
| Patents: | 0 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | POWDER;INTRAMUSCULAR, INTRAVENOUS | Strength | EQ 1MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
| Approval Date: | Jun 22, 1998 | TE: | RLD: | Yes | |||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | POWDER;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS | Strength | EQ 1MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
| Approval Date: | Jun 22, 1998 | TE: | RLD: | Yes | |||||
Complete Access Available with Subscription
